US FDA · Final guidance
FDA publishes final ICH E2B(R3) guidance for electronic safety reports
Official source date: · Source checked
FDA lists final implementation guidance for electronic individual case safety reports, covering E2B(R3) data elements, message specifications and backwards and forwards compatibility.
Who should review this?
Pharmacovigilance, safety-system validation and regulatory reporting teams.
What it means for pharmaceutical teams
The guidance and linked technical resources concern the electronic structure and exchange of individual case safety reports. FDA regional specifications should be considered alongside the ICH implementation materials for the applicable submission pathway.
Practical review checklist
PharmaEdges reading prompts for your own applicability review:
- Compare data mappings and message specifications with the implementation guide.
- Review compatibility materials, regional terminology and acknowledgement handling.
- Verify pathway-specific submission instructions and validate system changes before use.
Official source and verification
Read the US FDA source (opens in a new tab)
This article summarises the linked official material. The context and checklist are PharmaEdges explanatory commentary, not additional regulatory requirements. The source publication date is separate from this article’s publication date.
For a correction, contact PharmaEdges with the article URL and supporting source. Read our news publishing policy.
Related fda intelligence
- FDA finalises guidance on postapproval biosimilar manufacturing changes
- FDA proposes updated principles for container closure quality
- FDA issues inspection programme for CDER-regulated biologics
- FDA proposes guidance on responding to Form 483 observations